Trials / Terminated
TerminatedNCT05834543
Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy. The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin | TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy. |
| DRUG | Penpulimab injection, Paclitaxel, Cisplatin | Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy. |
| DRUG | TQB2618 injection, Penpulimab injection, TQB3617capsules | TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). |
Timeline
- Start date
- 2023-05-26
- Primary completion
- 2024-10-23
- Completion
- 2025-03-03
- First posted
- 2023-04-28
- Last updated
- 2025-07-16
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05834543. Inclusion in this directory is not an endorsement.